Redhill patents expiration
1. Aemcolo patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8263120 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 16 days from now) | |
| US8486446 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 16 days from now) | |
| US8741948 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 16 days from now) | |
| US8529945 | REDHILL | Oral antimicrobial pharmaceutical compositions |
May, 2025
(1 year, 16 days from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Nov 16, 2028 |
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2023 |
Drugs and Companies using RIFAMYCIN SODIUM ingredient
NCE-1 date: 17 November, 2027
Market Authorisation Date: 16 November, 2018
Treatment: Treatment of travelers' diarrhea caused by non-invasive strains of escherichia coli in adults
Dosage: TABLET, DELAYED RELEASE;ORAL
More Information on Dosage
AEMCOLO family patents
2. Talicia patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9498445 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| US9603806 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| US9050263 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| US11135172 | REDHILL | Rifabutin-based compositions and methods for treating Helicobacter pylori infection |
Feb, 2034
(9 years from now) | |
| US10238606 | REDHILL | Pharmaceutical compositions for the treatment of Helicobacter pylori |
Feb, 2034
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Generating Antibiotic Incentives Now(GAIN) | Nov 01, 2027 |
| New Product(NP) | Nov 01, 2022 |
Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient
Market Authorisation Date: 01 November, 2019
Treatment: Treatment of h. pylori infection in adults
Dosage: CAPSULE, DELAYED RELEASE;ORAL
More Information on Dosage
TALICIA family patents